{
  "metadata": {
    "case_id": 28,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T15:30:21.375982",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/28_NCT02864381.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/28_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.58
        ],
        [
          0.5,
          0.94
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Andecaliximab + Nivolumab",
            "type": "EXPERIMENTAL",
            "description": "Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).",
            "interventionNames": [
              "Drug: Andecaliximab",
              "Drug: Nivolumab"
            ]
          },
          "pred_item": {
            "label": "ADX + NIVO",
            "type": "EXPERIMENTAL",
            "description": "Patients received 800 mg andecaliximab (ADX) on day 1 (and every 2 weeks thereafter) administered via intravenous infusion over approximately 30 min, given prior to nivolumab (NIVO) (3 mg/kg) administered via intravenous infusion over approximately 60 min.",
            "interventionNames": [
              "Andecaliximab",
              "Nivolumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "label": "Nivolumab",
            "type": "ACTIVE_COMPARATOR",
            "description": "Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).",
            "interventionNames": [
              "Drug: Nivolumab"
            ]
          },
          "pred_item": {
            "label": "NIVO alone",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients received 3 mg/kg nivolumab (NIVO) via intravenous infusion over approximately 60 min on day 1, and every 2 weeks thereafter.",
            "interventionNames": [
              "Nivolumab"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.94,
          0.55
        ],
        [
          0.4,
          0.94
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Andecaliximab",
            "description": "800 mg administered via IV infusion",
            "armGroupLabels": [
              "Andecaliximab + Nivolumab"
            ],
            "otherNames": [
              "GS-5745"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Andecaliximab",
            "description": "A recombinant monoclonal antibody that targets the zinc-dependent matrix metalloproteinase-9 (MMP9). Administered intravenously.",
            "armGroupLabels": [
              "ADX + NIVO"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Nivolumab",
            "description": "3 mg/kg administered via IV infusion",
            "armGroupLabels": [
              "Andecaliximab + Nivolumab",
              "Nivolumab"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Nivolumab",
            "description": "An anti-PD-1 immune checkpoint inhibitor antibody. Administered intravenously.",
            "armGroupLabels": [
              "ADX + NIVO",
              "NIVO alone"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Objective Response Rate (ORR)",
            "description": "ORR was defined as the percentage of participants with confirmed overall best response of complete response (CR) or partial response (PR) after starting study drug but before starting any new chemotherapy or radiotherapy as assessed by the investigator according to Response Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.",
            "timeFrame": "Up to 41 weeks"
          },
          "pred_item": {
            "measure": "Overall Response Rate (ORR)",
            "description": "Investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 as the proportion of patients with best overall response of complete response (CR) or partial response (PR) after starting study drug and before starting any new anticancer therapy.",
            "timeFrame": "From start of study drug until start of new anticancer therapy, assessed every 8 weeks up to approximately 2 years"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.4,
          0.95,
          0.58,
          0.08
        ],
        [
          0.9,
          0.7,
          0.3,
          0.08
        ],
        [
          0.55,
          0.7,
          0.95,
          0.08
        ],
        [
          0.05,
          0.05,
          0.12,
          0.93
        ],
        [
          0.05,
          0.05,
          0.05,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "measure": "Progression Free Survival (PFS)",
            "description": "PFS was defined as the interval in months from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. The first definitive progressive disease (PD) was defined as the first radiation therapy, the first clinical PD, and the first confirmed imaging PD, whichever came first. Participants without PD or death and participants with PD after starting new anti-cancer therapy are censored at the last tumor assessment date.",
            "timeFrame": "Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months"
          },
          "pred_item": {
            "measure": "Progression-Free Survival (PFS)",
            "description": "Defined as the interval from the date of randomization to death (any cause) or the first definitive progressive disease (PD) (clinical PD, imaging PD, or radiation therapy).",
            "timeFrame": "From randomization to progression or death, assessed every 8 weeks during the study up to 5 years"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Overall Survival (OS)",
            "description": "OS was defined as the interval from the date of randomization to death from any cause. Surviving participants are censored at the last date known alive.",
            "timeFrame": "Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.0 months"
          },
          "pred_item": {
            "measure": "Overall Survival (OS)",
            "description": "Defined as the interval from the date of randomization to death from any cause.",
            "timeFrame": "From randomization to death, assessed every 3 months for up to 5 years"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "measure": "Duration of Response (DOR)",
            "description": "DOR was defined as the interval from the date of the first response (complete or partial response) was achieved to the earlier of the first documentation of definitive disease progression or death from any cause.",
            "timeFrame": "Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months"
          },
          "pred_item": {
            "measure": "Duration of Response",
            "description": "Evaluated as a secondary efficacy endpoint.",
            "timeFrame": "From date of first response until disease progression or death, up to 5 years"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)",
            "description": "An adverse event (AE) is any untoward medical occurrence in a clinical study participants administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events that are defined as AEs with onset dates on or after the first dose of andecaliximab/nivolumab and up to 30 days after permanent discontinuation of andecaliximab or 5 months after permanent discontinuation of nivolumab, or led to premature discontinuation of andecaliximab or nivolumab.",
            "timeFrame": "Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months"
          },
          "pred_item": {
            "measure": "Occurrence of Adverse Events (AEs) and Laboratory Abnormalities",
            "description": "Assessment of safety and tolerability.",
            "timeFrame": "From first dose through 30 days after last ADX dose and 5 months after last NIVO dose (Treatment up to 2 years)"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities",
            "description": "Treatment-emergent (Chemistry, Hematology, Coagulation, and Urinalysis) laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of andecaliximab plus 30 days or nivolumab plus 5 months. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment-emergent. Percentage of participants with any postbaseline Grade 1 or higher laboratory abnormality is reported.",
            "timeFrame": "Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months"
          },
          "pred_item": null
        }
      ]
    }
  ]
}